Literature DB >> 8740030

Organ-sparing treatment for ureteral carcinoma?

A Leitenberger1, A Beyer, J E Altwein.   

Abstract

OBJECTIVE: Nephroureterectomy (NUE) with a bladder cuff is the standard therapy for ureteral cancer. Based on an analysis of the literature and a retrospective study, this concept is questioned.
METHODS: Between 1980 and 1991, 40 patients with ureteral tumors underwent surgery at the Krankenhaus der Barmherzigen Brüder in Munich. Tumoral stages were pTa and pTl in 62% of the patients; 37% showed an invasive carcinoma. Radical surgery (NUE with bladder cuff) was performed in 22 patients and conservative treatment (ureterocystoneostomy or end-to-end-anastomosis) in 13 patients.
RESULTS: The median follow-up was 42 months in the conservative group and 59 months in the radical surgery group. A recurrence in the conservatively operated patients was observed only in primary invasive tumors (4/13), whereas none of the remaining patients had a recurrent tumor. In terms of time to progression and tumor-specific survival, there was a good correlation of the ureteral carcinoma according to grading and staging. In terms of survival, patients with superficial tumors run a similar course whether treated by conservative or radical surgery.
CONCLUSION: The conservative treatment of patients presenting with superficial ureteral lesions seems to be a good alternative to radical surgery.

Entities:  

Mesh:

Year:  1996        PMID: 8740030     DOI: 10.1159/000473759

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

2.  Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Jonathan L Silberstein; Nicholas E Power; Caroline Savage; Tatum V Tarin; Ricardo L Favaretto; Daniel Su; Matthew G Kaag; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2011-12-15       Impact factor: 7.450

3.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.